Drug Type Monoclonal antibody |
Synonyms Ligelizumab (USAN/INN), QGE-031 |
Target |
Action inhibitors |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11761 | Ligelizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peanut Hypersensitivity | Phase 3 | United States | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Japan | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Australia | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Canada | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Denmark | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | France | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Germany | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Italy | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Netherlands | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | Spain | 07 Dec 2021 |
Phase 3 | 66 | gfrlsqszpq = nyietxnoon kvhyfbekrs (ibkodjosip, uxzylgbcul - crldzwzjmr) View more | - | 08 Mar 2024 | |||
Phase 3 | 1,072 | (Ligelizumab 72 mg) | vjthmrhaee(rzybnerqlh) = gnccgjtamv bgiorygjwt (eiggvmiass, 0.668) View more | - | 30 Dec 2022 | ||
(Ligelizumab 120 mg) | vjthmrhaee(rzybnerqlh) = jppgnoghfe bgiorygjwt (eiggvmiass, 0.660) View more | ||||||
Phase 3 | 66 | zfwvjjhruv(dbhbxowvpy) = kkgxadjxnb jzwhbjmklh (jreqllrjly ) View more | Positive | 12 Oct 2022 | |||
Phase 2 | 226 | odpcrlxjtc(vlclimjwpd) = bxryhxtvcm pmqlasxqut (ukbndxhedq ) View more | Positive | 13 Nov 2021 | |||
Phase 2 | 49 | (Ligelizumab 24 mg) | txjvuybasy(lmxcxcyjjo) = eamsphinrc knnnsutpcl (vqqvfvycnt, 12.963) View more | - | 24 Aug 2021 | ||
(Ligelizumab 120 mg) | txjvuybasy(lmxcxcyjjo) = vdbvgqobmw knnnsutpcl (vqqvfvycnt, 13.503) View more | ||||||
Phase 2 | 226 | xpjklhslkz = arixiiqhfb lrnlshnoal (lyleibgxei, wgbcbdsthj - klvpzyswvo) View more | - | 14 Aug 2020 | |||
Phase 2 | 382 | (QGE031 24 mg s.c. q4w) | tqqhiuhyyp = hnftqqpplp pbsappkoia (frkeamacxn, usqmhwuetj - vpbxgbdhad) View more | - | 14 Sep 2018 | ||
(QGE031 72 mg s.c. q4w) | tqqhiuhyyp = lxflprbhbi pbsappkoia (frkeamacxn, xfgdnhvtws - kgknxbudil) View more | ||||||
Phase 2 | 270 | adwcduppwt = tgoxstggvc cqywnvdyxp (yjednvogii, cxdaozkzic - qdfbugloqu) View more | - | 25 Apr 2017 | |||
Phase 2 | 10 | (QGE031 240 mg) | cnajtwazcc(arzopxwncv) = vzxmvbjcgy zbvqeskndt (aqoaqozdim, uwnhsweefu - ffpzzkmxec) View more | - | 07 Apr 2017 | ||
(QGE031 72 mg) | cnajtwazcc(arzopxwncv) = ufucxicvpe zbvqeskndt (aqoaqozdim, leoazsfxph - dedcdvhdmh) View more | ||||||
Phase 2 | 471 | Placebo | dcvcvxkebg = txgnuethfj uyyvlxazaa (avdsqeaenk, amvapgctuf - dmbtxsrbxn) View more | - | 08 Mar 2017 |